Helix BioPharma Corp. (HBP.TO)
Develops antibody treatments to shrink solid tumors and improve cancer immunotherapy effectiveness.
1.45+0.01%Healthcare
StockGlow Score
Bearish
BearishBullish
1 year ago+34.3%
The outlook
Helix BioPharma is trading near the lower end of its 52-week range and below both its 50- and 200-day moving averages, reflecting a downtrend. Analyst coverage appears minimal, and the overall sentiment leans bearish. The stock remains depressed relative to recent price levels.
What’s behind the score
Price trendBelow its 50- & 200-day averages
52-week range11% of the way from its 52-week low to high
Market cap
$110.7M
52-wk high
5.40
52-wk low
0.95
50-day avg
1.49
200-day avg
1.92
Trailing P/E
—